# J&J Secures Exclusive $2.58B Option to Acquire In Vivo CAR-T Developer Sail Biomedicines

> ma · REPORTED · 2026-07-31

Johnson & Johnson announced a strategic collaboration and exclusive $2.58 billion option to acquire Sail Biomedicines, a biotechnology company developing in vivo CAR-T therapies for immune-mediated diseases, joining a wave of major pharma firms investing in next-generation cell therapy approaches.

About Johnson & Johnson: Sail Biomedicines is a biotechnology company developing in vivo CAR-T therapies — treatments designed to engineer a patient's own T cells inside the body to attack immune-mediated disease targets — serving patients with serious autoimmune conditions.

- Company: Johnson & Johnson
- Sector: biotech
- Primary source: https://www.biopharmadive.com/news/johnson-johnson-sail-option-acquire-in-vivo-car-t/826589/

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.